Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 3/2006

01-05-2006 | HIV Treatment Research Article

Neurocognitive Aspects of Medication Adherence in HIV-Positive Injecting Drug Users

Authors: Drenna Waldrop-Valverde, Raymond L. Ownby, Frances L. Wilkie, Alison Mack, Mahendra Kumar, Lisa Metsch

Published in: AIDS and Behavior | Issue 3/2006

Login to get access

Abstract

Cognitive deficits are associated with nonadherence to HIV medications. HIV-positive injecting drug users (IDUs) are at particular risk for nonadherence and cognitive barriers to adherence specific to this population should therefore be identified. The present study assessed the relation of three domains of cognitive functioning, executive functions, memory, and psychomotor speed, to self-reported antiretroviral adherence in a sample of HIV-positive IDUs. Depression, use of alcohol, heroin, cocaine/crack, or marijuana in the last week were also included in the models. Logistic regression analyses showed that only psychomotor slowing was significantly associated with nonadherence. Executive functions, memory, depression, and active alcohol and substance use were unrelated to adherence. No other studies to date have exclusively linked psychomotor slowing to nonadherence in HIV infection. Psychomotor slowing among our study sample was severe and suggests that when evident, such slowing may be a valuable determinant for antiretroviral adherence among IDUs.
Literature
Ahmad, S., Ahmad, H., and Bindra, G. (1989). Cognitive impairment in chronic heroin addicts. Journal of Personality and Clinical Studies, 5, 237–240.
Albert, S. M., Weber, C. M., Todak, G., Polanco, C., Clouse,R., McElhiney, M., Rabkin, J., Stern, Y., Marder, K.(1999). An observed performance test of medication management ability in HIV: Relation to neuropsychological status and medication adherence outcomes. AIDS and Behavior, 3, 121–128.CrossRef
Arnsten, J. H., Demas, P. A., Farzadegan, H., Grant, R. W., Gourevich, M. N., Chang, C., et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clinical Infectious Diseases, 33, 1417–1423.CrossRefPubMed
Arnsten, J. H., Demas, P. A., Grant, R. W., Gourevitch, M. N., Farzadegan, H., Howard, A. A., et al. (2002). Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. Journal of General Internal Medicine, 17, 377–381.CrossRefPubMed
Avants, S. K., Margolin, A., Warburton, L. A., Hawkins, K. A., and Shi, J. (2001). Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. The American Journal on Addictions, 10, 69–78.CrossRefPubMed
Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., et al. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14, 357–366.CrossRefPubMed
Basso, M. R., and Bornstein, R. A. (2000). Neurobehavioral consequences of substance abuse and HIV infection. Journal of Psychopharmacology, 14, 228–237.PubMedCrossRef
Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., and Erbaugh, J. (1961). An inventory for measuring depression. Archives of General Psychiatry, 4, 561–571.PubMed
Benton, A. L., Hamsher, K., and Sivan, A. B. (1983). Multilingual Aphasia Examination (3rd ed.). Iowa City, IA: AJA Associates.
Berry, J., van Gorp, W. G., Herzberg, D. S., Hinkin, C., Boone, K., Steinman, L., et al. (1993). Neuropsychological deficits in abstinent cocaine abusers: Preliminary findings after two weeks of abstinence. Drug and Alcohol Dependence, 32, 231–237.CrossRefPubMed
Bono, G., Mauri, M., Sinforiani, E., Barbarini, G., Minoli, L., and Fea, M. (1996). Longitudinal neuropsychological evaluation of HIV-infected intravenous drug users. Addiction, 91, 263–268.CrossRefPubMed
Bornstein, R. A., Pace, P., Rosenberger, P., Nasrallah, H. A., Para, M. F., Whitacre, C. C., et al. (1993). Depression and neuropsychological performance in asymptomatic HIV infection. American Journal of Psychiatry, 150, 922–927.PubMed
Carrieri, M. P., Chesney, M. A., Spire, B., Loundou, A., Sobel, A., Lepeu, G., Moatti, J. P., and the MANIF Study Group. (2003). Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. International Journal of Behavioral Medicine, 10, 1–14.CrossRefPubMed
Catz, S. L., Kelly, J. A., Bogart, L. M., Benotsch, E. G., and McAuliffe, T. L. (2000). Patterns, correlates and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology, 19, 124–133.CrossRefPubMed
Cohen, R. A., Boland, R., Paul, R., Tashima, K. T., Schoenbaum, E. E., Celentano, D. D., et al. (2001). Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV infected women. AIDS, 15, 341–345.CrossRefPubMed
Cummings, J. L., and Benson, D. F. (1992). Dementia: A clinical approach (2nd ed.). Boston: Butterworth Heinemann.
The Dana Consortium. (1996). Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Neurology, 47, 1247–1253.
D’Elia, L., Satz, P., Uchiyama, C. L., and White, T. (1996). Color trails 1 and 2. Odessa, FL: Psychological Assessment Resources.
Ferrando, S., van Gorp, W., McElhiney, M., Goggin, K., Sewell, M., and Rabkin, J. (1998). Highly active antiretroviral treatment in HIV infection: Benefits for neuropsychological function. AIDS, 12, F65–F70.CrossRefPubMed
First, M. B., Spitzer, R. L., Gibbon, M., and Williams, J. B. (1995). Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (Version 2.0). New York: New York State Psychiatric Institute.
Galea, S., and Vlahov, D. (2002). Social determinants and the health of drug users: Socioeconomic status, homeless, and incarceration. Public Health Reports, 117, S135–S145.PubMed
Gordillo, V., del Amo, J., Soriano, V., and Gonzalez-Lahoz, J. (1999). Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS, 13, 1763–1769.CrossRefPubMed
Grant, I., Adams, K. M., Carlin, A. S., Rennick, P. M., Judd, L. L., Schooff, K., et al. (1978). Neuropsychological effects of polydrug abuse. In D. R. Wesson, A. S. Carlin, K. M. Adams, and G. Beschner (Eds.), Polydrug abuse. The results of a national collaborative study (pp. 223–261). New York: Academic.
Grant, I., Atkinson, J. H., Hesselink, J. R., Kennedy, C. J., Richman, D. D., and Spector, S. A., et al. (1987). Evidence for early central nervous system involvement in the Acquired immunodeficiency virus (HIV) infections. Annals of Internal Medicine, 107, 828–836.PubMed
Grant, I., and Martin, A. (1994). Neurocognitive disorders associated with HIV-1 infection. In I. Grant and A. Martin (Eds.), Neuropsychology of HIV-1 infection (pp. 3–19). New York: Oxford University Press.
Hinkin, C. H., Castellon, S. A., Durvasula, R. S., Hardy, D. J., Lam, M. N., and Mason, K. I., et al. (2002). Medication adherence among HIV+ adults. Neurology, 59, 1944–1950.PubMed
Hinkin, C. H., Hardy, D. J., Mason, K. I., Castellon, S. A., Durvasula, R. S., Lam, M. N., et al. (2004). Medication adherence in HIV-infected adults: Effect of patient, age, cognitive status, and substance abuse. AIDS, 18, S19–S25.CrossRefPubMed
Howard, A. A., Arnsten, J. H., Lo, Y., Vlahov, D., Rich, J. D., Schuman, P., Stone, V. E., Smith, D. K., Schoenbaum, E. E., and the HER Study Group. (2002). A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS, 16, 2175–2182.CrossRefPubMed
Karon, J. M., Fleming, P. L., Steketee, R. W., and DeCock, K. M. (2001). HIV in the United States at the turn of the century. American Journal of Public Health, 91, 1060–1068.PubMedCrossRef
Liu, H., Golin, C. E., Miller, L. G., Hays, R. D., Beck, C. K., Sanadaji, S., et al. (2001). A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134, 968–977.PubMed
Lucas, G. M., Cheever, L. W., Chaisson, R. E., and Moore, R. D. (2001). Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes, 27, 251–259.PubMed
Mannheimer, S., Friedland, G., Matts, J., Child, C., and Chesney, M. (2002). The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases, 34, 1115–1121.CrossRefPubMed
Martens, W. H. (2001). A review of physical and mental health in homeless persons. Public Health Review, 29, 13–33.
Meek, P. S., Clark, H. W., and Solana, V. L. (1989). Neurocognitive impairment: The unrecognized component of dual diagnoses in substance abuse treatment. Journal of Psychoactive Drugs, 21, 153–160.PubMed
Montaner, J. S. G., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B., et al. (1998). A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients. JAMA, 279, 930–937.CrossRefPubMed
Murphy, E. L., Collier, A. C., Kalish, L. A., Assmann, S. F., Para, M. F., Flanigan, T. P., et al. (2001). Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Annals of Internal Medicince, 135, 17–26.
Navia, B. A., Jordan, B. D., and Price, R. W. (1986). The AIDS dementia complex: I. Clinical features. Annals of Neurology, 19, 517–524.CrossRefPubMed
Paterson, D., Swindells, S., Mohr, J., Brestor, M., Vergis, R., Squier, C., et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133, 21–30.PubMed
Paterson, D. L., Potoski, B., and Capitano, B. (2002). Measurement of adherence to antiretroviral medications. Journal of Acquired Immune Deficiency Syndromes, 31, S103–S106.PubMed
Sacktor, N., McDermott, M. P., Marder, K., Schiffito, G., Selnes, O. A., McArthur, J. C., et al. (2002). HIV-associated cognitive impairment before and after the advent of combination therapy. Journal of Neurovirology, 8, 136–142.CrossRefPubMed
Sacktor, N., Skolasly, R. L., Tarwater, P. M., McArthur, J. C., Selnes, O. A., Becker, J., et al. (2003). Response to systemic HIV viral load suppression correlates with psychomotor speed performance. Neurology, 61, 567–569.PubMed
Sankoh, A. J., Huque, M. F., and Dubey, S. D. (1997). Some comments on frequently used multiple endpoint adjustments methods in clinical trials. Statistics in Medicine, 16, 2529–2542.CrossRefPubMed
Selnes, O. A., Galai, N., McArthur, J. C., Cohn, S., Royal, W., Esposito, D., et al. (1997). HIV infection and cognition in intravenous drug users: Long-term follow-up. Neurology, 48, 223–230.PubMed
Smith, A. (2000). Symbol Digit Modalities Test: Manual. Los Angeles: Western Psychological Services.
Stern, R. A., Silva, S. G., Chaisson, N., and Evans, D. L. (1996). Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection. Archives of Neurology, 53, 148–153.PubMed
Stevens, J. (1996). Applied Multivariate Statistics for the Social Sciences (3rd ed.). Mahwah, NJ: Erlbaum.
Strickland, T. L., Miller, B. L., Kowell, A., and Stein, R. (1993). Neurobiology of cocaine-induced organic brain impairment: Contribution from functional neuroimaging. Neuropsychology Review, 8, 1–9.CrossRef
Suarez, S., Baril, L., Stankoff, B., Khellaf, M., Dubois, B., Lubetzki, C., et al. (2001). Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy. AIDS, 15, 195–200.CrossRefPubMed
Tesoriero, J., French, T., Weiss, L., Waters, M., Finkelstein, R., and Agins, B. (2003). Stability of adherence to highly active antiretroviral therapy over time among clients enrolled in the treatment adherence demonstration project. JAIDS: Journal of the Acquired Immune Deficiency Syndromes, 33, 484–493.
Tiffin, J. (1968). Purdue Pegboard: Examiner manual. Chicago: Science Research Associates.
Tombaugh, T. N., Kozak, J., and Rees, L. (1996). Normative data for the controlled oral word association test. In O. Spreen and E. Strauss (Eds.), A compendium of neuropsychological tests: Administration, norms and commentary (2nd ed.). New York: Oxford.
Tucker, J. S., Burnam, A., Sherbourne, C. D., Kung, F. Y., and Gifford, A. L. (2003). Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. The American Journal of Medicine, 114, 573–580.CrossRefPubMed
Turner, B. J., Laine, C., Cosler, L., and Hauck, W. W. (2003). Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. Journal of General Internal Medicine, 18, 248–257.CrossRefPubMed
Wagner, G. J. (2002). Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care and STDs, 16, 599–608.CrossRefPubMed
Wainberg, M. A., and Friedland, G. (1998). Public health implications of antiretroviral therapy and HIV drug resistance. JAMA, 279, 1977–1983.CrossRefPubMed
Wall, T. L., Sorensen, J. L., Batki, S. L., Delucchi, K. L., London, J. A., and Chesney, M. A. (1995). Adherence to zidovudine (AZT) among HIV-infected methadone patients: A pilot study of supervised therapy and dispensing compared to usual care. Drug and Alcohol Dependence, 37, 261–269.CrossRefPubMed
Wechsler, D. (1997). Wechsler adult intelligence scale Manual (3rd ed.). New York: The Psychological Corporation.
Wilkie, F. L., Eisdorfer, C., Morgan, R., Loewenstein, D. A., and Szapocznik, J. (1990). Cognition in early human immunodeficiency virus infection. Archives of Neurology, 47, 433–440.PubMed
Wilkinson, G. S. (1993). The Wide Range Achievement Test Administration Manual (3rd ed.). Wilmington, DE: Wide Range.
Yeudall, L. T., Fromm, D., Reddon, J. R., and Stefanyk, W. O. (1986). Normative data stratified by age and sex for 12 neuropsychological tests. Journal of Clinical Psychology, 42, 918–946.CrossRef
Metadata
Title
Neurocognitive Aspects of Medication Adherence in HIV-Positive Injecting Drug Users
Authors
Drenna Waldrop-Valverde
Raymond L. Ownby
Frances L. Wilkie
Alison Mack
Mahendra Kumar
Lisa Metsch
Publication date
01-05-2006
Publisher
Springer US
Published in
AIDS and Behavior / Issue 3/2006
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-005-9062-6

Other articles of this Issue 3/2006

AIDS and Behavior 3/2006 Go to the issue

Original Article

Lipodystrophy Severity Does Not Contribute to HAART Nonadherence

Africa and AIDS

HIV Education Needs Among Sudanese Immigrants and Refugees in the Midwestern United States

HIV Treatment Research Article

Social Support, Disclosure, and Use of Antiretroviral Therapy

Other Research Articles

Alcohol and Sexual HIV Risk Behavior Among Problem Drinking Men Who Have Sex With Men: An Event Level Analysis of Timeline Followback Data

HIV Treatment Research Article

Substance Abuse and Medication Adherence Among HIV-Positive Women with Histories of Child Sexual Abuse

OriginalPaper

The Influence of Power on HIV Risk Among Pregnant Women in Rural Haiti
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits